지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.3
- 수록면
- 175 - 180 (6page)
- DOI
- 10.3349/ymj.2022.0287
이용수
초록· 키워드
오류제보하기
Purpose: Diabetes and dyslipidemia are leading causes of mortality and morbidity. According to international guidelines, statins are the cornerstone of treatment in patients with diabetes and/or dyslipidemia. However, statins and antidiabetic agents have op posite pharmacological effects, because statins, particularly atorvastatin and rosuvastatin, impair glucose homeostasis, increas ing the risk of new-onset diabetes, whereas antidiabetic drugs improve glycemic homeostasis. The aim of this study was to inves tigate the effect of atorvastatin, rosuvastatin, and pitavastatin on glucose homeostasis in patients with type 2 diabetes mellitus (T2DM) and dyslipidemia during stable treatment with hypoglycemic drugs.
Materials and Methods: The study was conducted as a pilot, prospective, randomized, open label, parallel group with blinded endpoints (PROBE) study. Of 180 recruited patients with T2DM and dyslipidemia, 131 were randomized to atorvastatin (n=44), rosuvastatin (n=45), and pitavastatin (n=42) and treated for 6 months.
Results: Fasting plasma glucose (FPG) marginally decreased in patients assigned to atorvastatin (-3.5 mg/dL, p=0.42) and rosuvas tatin (-6.5 mg/dL, p=0.17), while it decreased much more in patients treated with pitavastatin (-19.0 mg /dL, p<0.001). Mean gly cated hemoglobin A1c (HbA1c ) values remained unchanged during treatment with atorvastatin (-0.10%, p=0.53) and rosuvastatin (0.20%, p=0.40), but were significantly reduced with pitavastatin (-0.75%, p=0.01). Atorvastatin, rosuvastatin, and pitavastatin sig nificantly lowered (p<0.001) plasma levels of total cholesterol, low-density lipoprotein-cholesterol, and triglycerides, while high density lipoprotein-cholesterol (HDL-C) levels increased significantly (p=0.04) only in the pitavastatin group.
Conclusion: The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvas tatin in patients with T2DM and concomitant dyslipidemia. Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin. Although the pharmacological mecha nism of pitavastatin on glucose homeostasis in patients with T2DM during stable antidiabetic therapy is not known, it can be as sumed that pitavastatin has less drug interaction with hypoglycemic agents or that it increases plasma levels of adiponectin.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial
Journal of Yeungnam Medical Science
2024 .07
-
Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2017 .01
-
Pitavastatin Induces Apoptosis of Cutaneous Squamous Cell Carcinoma Cells through Geranylgeranyl Pyrophosphate Dependent c-Jun N-Terminal Kinase Activatio
Annals of Dermatology
2023 .04
-
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Endocrinology and Metabolism
2017 .01
-
Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol
Korean Circulation Journal
2016 .01
-
Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
대한뇌졸중학회지
2016 .01
-
A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin
Tuberculosis and Respiratory Diseases
2015 .01
-
스타틴과 당뇨병 발생 위험
대한의사협회지
2017 .01
-
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
Diabetes and Metabolism Journal
2019 .01
-
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
Diabetes and Metabolism Journal
2019 .01
-
Clinical Benefit of Statins in Korean Patients with Acute Myocardial Infarction: Experience of the Korea Acute Myocardial Infarction Registry
지질·동맥경화학회지
2020 .01
-
Impact of Statin Treatment on Strut Coverage after Drug-Eluting Stent Implantation
Yonsei Medical Journal
2015 .01
-
Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
Journal of Cardiovascular Imaging
2021 .01
-
Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin
지질·동맥경화학회지
2020 .01
-
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
Yonsei Medical Journal
2024 .01
-
Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
대한뇌졸중학회지
2023 .05
-
Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial
지질·동맥경화학회지
2019 .01
-
소아청소년 이상지혈증의 유병률 및 치료
대한의사협회지
2021 .01
-
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
지질·동맥경화학회지
2022 .09
-
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Journal of Pharmaceutical Investigation
2018 .05
이 논문의 저자 정보
최근 본 자료
댓글(0)
0